Losartan Potassium
Product Images NDC 66336-666

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 66336-666). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0665-xx (Ndc 66336 0665 Xx Teva)

Packaging label for Losartan Potassium 50 mg tablets from Dispensing Solutions, Inc. The label includes dosage instructions, warnings, and lot information with a sample lot number and expiration date. The package is marked Rx only and contains multiple small labels with product and barcode details, indicating a bulk supply format.*

FDA Label Image

Ndc 66336-0666-xx (Ndc 66336 0666 Xx Teva)

Losartan Potassium 25 mg tablet bottle label by Dispensing Solutions, Inc. The label includes the drug name, strength, dosage form, sample lot and expiration dates, NDC 66336-0666-XX, and a warning not to take if pregnant. DispenseQuick branding and manufacturer information are visible, along with barcodes and general storage instructions.*

FDA Label Image

Chem Structure For Losartan Potassium (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 01)

Chemical structure of Losartan Potassium, depicting its molecular components including the tetrazole ring and chlorinated pyrimidine ring along with the potassium ion.*

FDA Label Image

Figure 1 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 02)

A line graph comparing the percentage of patients with a primary endpoint over time (study months) between Atenolol and Losartan Potassium. The graph shows adjusted risk reduction data with Losartan Potassium referenced, indicating statistical results including a p-value of 0.021 over a 66-month period.*

FDA Label Image

Figure 2 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months for Atenolol and Losartan Potassium. The graph shows a lower stroke rate for Losartan Potassium, with an adjusted risk reduction of 25%, p=0.001.*

FDA Label Image

Figure 3 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 04)

A forest plot comparing the hazard ratios and 95% confidence intervals of Losartan Potassium versus Atenolol in preventing primary composite events and fatal/non-fatal strokes. The chart breaks down results by patient demographics and clinical conditions, with symbols indicating proportional sample size and confidence intervals around hazard ratio points.*

FDA Label Image

Figure 4 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 05)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups, showing risk reduction of 16.1% for Losartan Potassium with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.